Cirrhosis Research Study
Researchers at the Medical University of South Carolina are looking for a better way to treat MASH cirrhosis.
Fast Facts
Ages 18-75
Diagnosed with Cirrhosis
Compensation Provided
Conducted in Charleston, SC
Study Background
The Medical University of South Carolina is conducting a research study on a potential treatment for cirrhosis.
MASH-related cirrhosis is a serious liver condition with limited treatment options. Researchers are working to find better therapies that can help reduce liver damage and improve overall health. This study is focused on pegozafermin, a medication designed to target liver inflammation, support metabolism, and promote tissue repair. Early research suggests that it may help slow down or even reverse liver scarring (fibrosis), offering new hope for people with MASH-related cirrhosis.
The main goal of this study is to determine whether pegozafermin can effectively reduce liver fibrosis. By participating, individuals will help researchers better understand how this treatment works and whether it could become a new option for managing MASH-related cirrhosis in the future.
Study Background
The Medical University of South Carolina is conducting a research study on a potential treatment for cirrhosis.
MASH-related cirrhosis is a serious liver condition with limited treatment options. Researchers are working to find better therapies that can help reduce liver damage and improve overall health. This study is focused on pegozafermin, a medication designed to target liver inflammation, support metabolism, and promote tissue repair. Early research suggests that it may help slow down or even reverse liver scarring (fibrosis), offering new hope for people with MASH-related cirrhosis.
The main goal of this study is to determine whether pegozafermin can effectively reduce liver fibrosis. By participating, individuals will help researchers better understand how this treatment works and whether it could become a new option for managing MASH-related cirrhosis in the future.
Additional Information
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18-75
- Diagnosed with MASH cirrhosis
- No history of liver transplantation
- No heart failure
This study involves a total of 24 visits over a span of 5 years, with approximately half of the visits conducted over the phone.
A total compensation of $1360 will be provided to participants who complete this study. Reimbursement for transportation is also offered.
There is no cost for you to participate in our research study.
